卡麦角林对分泌促卵泡激素的垂体腺瘤的影响。
Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
作者信息
Leese G, Jeffreys R, Vora J
机构信息
Department of Medicine, Royal liverpool University Hospital, UK.
出版信息
Postgrad Med J. 1997 Aug;73(862):507-8. doi: 10.1136/pgmj.73.862.507.
Abstract
A patient with a pituitary adenoma secreting follicle-stimulating hormone with co-existent primary hyperaldosteronism is described. After his second transsphenoidal surgery, the patient developed a Staphylococcus aureus pituitary abscess. Symptoms improved after abscess drainage. Subsequent cabergoline therapy arrested the deterioration of symptoms. and decreased serum follicle-stimulating hormone concentrations. Cabergoline may be a useful treatment for aggressively growing non-prolactin-secreting pituitary adenomas.
摘要
本文描述了一名患有分泌促卵泡生成素的垂体腺瘤并伴有原发性醛固酮增多症的患者。在其第二次经蝶窦手术后，该患者发生了金黄色葡萄球菌垂体脓肿。脓肿引流后症状改善。随后的卡麦角林治疗阻止了症状恶化，并降低了血清促卵泡生成素浓度。卡麦角林可能是治疗侵袭性生长的非泌乳素分泌型垂体腺瘤的一种有效疗法。
相似文献
1
Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.卡麦角林对分泌促卵泡激素的垂体腺瘤的影响。
Postgrad Med J. 1997 Aug;73(862):507-8. doi: 10.1136/pgmj.73.862.507.
2
Effectiveness of cabergoline in reducing follicle-stimulating hormone and prolactin hypersecretion from pituitary macroadenoma in an infertile woman.
Fertil Steril. 1994 Oct;62(4):882-5. doi: 10.1016/s0015-0282(16)57021-6.
3
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.分泌催乳素和临床无功能垂体腺瘤患者中激素水平及肿瘤大小对喹高利特和卡麦角林的反应：123I-甲氧基苄胺垂体闪烁显像的预测价值
Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45. doi: 10.1046/j.1365-2265.2000.00951.x.
4
In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.临床无功能垂体腺瘤患者的体内分泌潜能及奥曲肽与卡麦角林联合治疗的效果
Clin Endocrinol (Oxf). 2001 Jan;54(1):23-30. doi: 10.1046/j.1365-2265.2001.01172.x.
5
Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma.卡麦角林对促性腺激素腺瘤中α亚基和促卵泡激素分泌的调节作用
J Endocrinol Invest. 2000 Jul-Aug;23(7):463-6. doi: 10.1007/BF03343756.
6
ACTH silent adenoma shrinking under cabergoline.促肾上腺皮质激素无功能腺瘤在卡麦角林治疗下缩小
Eur J Endocrinol. 2001 Jan;144(1):51-7. doi: 10.1530/eje.0.1440051.
7
Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.使用每周一次的多巴胺激动剂卡麦角林治疗分泌催乳素的大腺瘤。
J Clin Endocrinol Metab. 1996 Jun;81(6):2338-43. doi: 10.1210/jcem.81.6.8964874.
8
Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.卡麦角林治疗生长激素及生长激素/催乳素分泌型垂体瘤。
Pituitary. 2004;7(1):21-30. doi: 10.1023/b:pitu.0000044630.83354.f0.
9
Dopaminergic treatment of nonfunctioning pituitary adenomas.无功能垂体腺瘤的多巴胺能治疗
Nat Clin Pract Endocrinol Metab. 2007 Aug;3(8):554-5. doi: 10.1038/ncpendmet0558. Epub 2007 Jun 19.
10
Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.无功能垂体腺瘤中多巴胺受体2型的表达谱及对卡麦角林治疗的体内反应
Clin Endocrinol (Oxf). 2015 May;82(5):739-46. doi: 10.1111/cen.12684. Epub 2015 Jan 8.
引用本文的文献
1
Preparation and characterization of vaginal suppository of semisynthetic derivatives of ergot alkaloids cabergoline.麦角生物碱半合成衍生物卡麦角林阴道栓剂的制备与表征
Saudi Pharm J. 2023 Dec;31(12):101849. doi: 10.1016/j.jsps.2023.101849. Epub 2023 Nov 4.
2
Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma.卡麦角林对促性腺激素腺瘤中α亚基和促卵泡激素分泌的调节作用
J Endocrinol Invest. 2000 Jul-Aug;23(7):463-6. doi: 10.1007/BF03343756.
本文引用的文献
1
Effectiveness of cabergoline in reducing follicle-stimulating hormone and prolactin hypersecretion from pituitary macroadenoma in an infertile woman.
Fertil Steril. 1994 Oct;62(4):882-5. doi: 10.1016/s0015-0282(16)57021-6.
2
Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.溴隐亭对催乳素分泌性垂体瘤及其他垂体瘤的临床和病理影响。
J Neurosurg. 1984 Jan;60(1):1-7. doi: 10.3171/jns.1984.60.1.0001.
3
Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producing pituitary adenoma by bromocriptine.溴隐亭降低垂体促卵泡激素腺瘤中促卵泡激素（FSH）的分泌
J Clin Endocrinol Metab. 1984 Dec;59(6):1220-3. doi: 10.1210/jcem-59-6-1220.
4
The effect of dopamine agonist therapy on large functionless pituitary tumours.多巴胺激动剂疗法对大型无功能垂体瘤的影响。
Clin Endocrinol (Oxf). 1985 May;22(5):679-86. doi: 10.1111/j.1365-2265.1985.tb03004.x.
5
Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine.无功能垂体腺瘤在溴隐亭治疗期间不会消退，但具有可结合溴隐亭的膜结合多巴胺受体。
Clin Endocrinol (Oxf). 1986 Nov;25(5):561-72. doi: 10.1111/j.1365-2265.1986.tb03610.x.
6
Medical treatment of pituitary adenomas: effects on tumor growth.垂体腺瘤的医学治疗：对肿瘤生长的影响
J Endocrinol Invest. 1985 Jun;8(3):273-81. doi: 10.1007/BF03348493.
7
Bromocriptine therapy for non-functioning pituitary adenoma.
Clin Endocrinol (Oxf). 1989 May;30(5):475-84. doi: 10.1111/j.1365-2265.1989.tb01418.x.
8
Follicle-stimulating hormone- and alpha-subunit-secreting pituitary tumor treated with bromocriptine.用溴隐亭治疗的分泌促卵泡激素和α亚基的垂体肿瘤
J Clin Endocrinol Metab. 1985 Sep;61(3):580-4. doi: 10.1210/jcem-61-3-580.
9
Acute effects of Parlodel-LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma.一名分泌促卵泡生成素的垂体腺瘤患者使用长效溴隐亭（Parlodel-LAR）的急性效应及对溴隐亭长期治疗的反应
J Endocrinol Invest. 1991 Feb;14(2):135-8. doi: 10.1007/BF03350285.
10
Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma.
Clin Endocrinol (Oxf). 1992 Feb;36(2):171-6. doi: 10.1111/j.1365-2265.1992.tb00953.x.
Zotero 插件